Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy

about

Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy

Item

http://www.wikidata.org/entity/Q35884411

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Real-world cost analysis of ch ...... entire course of chemotherapy

@ast

Real-world cost analysis of ch ...... entire course of chemotherapy

@en

type

Item

label

Real-world cost analysis of ch ...... entire course of chemotherapy

@ast

Real-world cost analysis of ch ...... entire course of chemotherapy

@en

prefLabel

Real-world cost analysis of ch ...... entire course of chemotherapy

@ast

Real-world cost analysis of ch ...... entire course of chemotherapy

@en

P1476

Real-world cost analysis of ch ...... entire course of chemotherapy

@en

P2093

Hiroyuki Sakamaki

http://www.w3.org/2001/XMLSchema#string

Hisanori Shimizu

http://www.w3.org/2001/XMLSchema#string

Jun-Ichiro Murayama

http://www.w3.org/2001/XMLSchema#string

Naoki Ikegami

http://www.w3.org/2001/XMLSchema#string

Shuichi Yajima

http://www.w3.org/2001/XMLSchema#string

Shunya Ikeda

http://www.w3.org/2001/XMLSchema#string

P2860

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

In Japan, all-payer rate setting under tight government control has proved to be an effective approach to containing costs.

A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

P2888

s12913-015-1253-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12913-015-1253-X

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290201432

http://www.w3.org/2001/XMLSchema#string

P6179

1010257956

http://www.w3.org/2001/XMLSchema#string

P698

26728154

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

chemotherapy

P932

4698819

http://www.w3.org/2001/XMLSchema#string